Andrew L. Coveler

Oncology
825 Eastlake Ave E
Seattle, WA 98109

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 56 publications

Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001.

Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001.

Journal: Cancers
Published: January 03, 2026

Correction: Chang et al. Exercise Guidelines in Pancreatic Cancer Based on the Dietz Model. Cancers 2025, 17, 630.

Correction: Chang et al. Exercise Guidelines in Pancreatic Cancer Based on the Dietz Model. Cancers 2025, 17, 630.

Journal: Cancers
Published: December 25, 2025

Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

Journal: JCO oncology practice
Published: December 15, 2025

Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.

Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.

Journal: Nature medicine
Published: October 15, 2025

Prospective pilot evaluation of dark borosilicate oral contrast media for the evaluation of the stomach and small bowel using CT.

Prospective pilot evaluation of dark borosilicate oral contrast media for the evaluation of the stomach and small bowel using CT.

Journal: Abdominal radiology (New York)
Published: September 23, 2025

Phase Ia/Ib Study of Afatinib with Capecitabine in Patients with Refractory Solid Tumors and Pancreaticobiliary Cancers.

Phase Ia/Ib Study of Afatinib with Capecitabine in Patients with Refractory Solid Tumors and Pancreaticobiliary Cancers.

Journal: Cancers
Published: March 16, 2025

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis.

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis.

Journal: Nature communications
Published: March 06, 2025

Targeting metabolism in pancreatic ductal adenocarcinoma: challenges and insights from the AVENGER 500 trial.

Targeting metabolism in pancreatic ductal adenocarcinoma: challenges and insights from the AVENGER 500 trial.

Journal: Journal of gastrointestinal oncology
Published: January 22, 2025

Exercise Guidelines in Pancreatic Cancer Based on the Dietz Model.

Exercise Guidelines in Pancreatic Cancer Based on the Dietz Model.

Journal: Cancers
Published: January 02, 2025

A Phase II Study of Denileukin Diftitox in Patients with Advanced Treatment Refractory Breast Cancer.

A Phase II Study of Denileukin Diftitox in Patients with Advanced Treatment Refractory Breast Cancer.

Journal: Vaccines
Published: October 19, 2024

Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer.

Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer.

Journal: ESMO open
Published: August 23, 2024

Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.

Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.

Journal: Gynecologic oncology
Published: August 09, 2024
Showing 1-12 of 56

Last Updated: 09/26/2026